Mepivacaina B.Braun

Mepivacaine, the active ingredient in Mepivacaina B.Braun, is a local anesthetic presented as a solution for epidural, intra‑articular and intradermal use. It provides temporary loss of sensation for surgical, dental and diagnostic procedures in adult patients. GNH USA supplies Mepivacaina B.Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepivacaine is a local anesthetic used to block nerve conduction in various clinical settings.

- Surgical and dental procedures: provides local anesthesia to facilitate pain‑free surgery or dental work. - Epidural analgesia: delivers analgesia for labor, postoperative pain, or chronic pain management. - Intra‑articular injection: enables joint anesthesia for arthroscopic or therapeutic procedures. - Intradermal infiltration: used for diagnostic skin testing or minor procedures requiring superficial anesthesia.

Mepivacaina B.Braun may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Transient burning or tingling at the injection site - Mild hypotension - Nausea - Dizziness

Serious or Rare Side Effects: - Cardiac arrhythmias - Seizures - Methemoglobinemia - Anaphylactic allergic reactions

Prior to administration, consider the following safety measures.

- Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid in patients with severe heart block or conduction disorders. - Neurological disorders: use cautiously in patients with epilepsy or seizure history. - Pregnancy and lactation: evaluate risk‑benefit, limited data are available. - Dosage limits: adhere to the maximum recommended dose per procedure. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Mepivacaina B.Braun can interact with other medications; monitor patients accordingly.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Beta‑blockers: increase risk of bradycardia and hypotension. - General anesthetics (e.g., halothane): potentiate central nervous system depression.

Moderate Interactions (Monitor Closely): - MAO inhibitors: may increase risk of hypertension. - Diuretics: may alter plasma protein binding of the anesthetic. - Other local anesthetics: cumulative toxicity risk when used together.